Chemotherapy in Treating Patients With Recurrent Malignant Glioma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00002986
First received: November 1, 1999
Last updated: February 15, 2013
Last verified: February 2013

November 1, 1999
February 15, 2013
February 1997
May 2004   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00002986 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Phase I Treatment of Adults With Primary Malignant Glioma With Topotecan (NSC #609699) Plus BCNU (NSC #409962)

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent primary malignant glioma.

OBJECTIVES:

  • Determine the maximum tolerated dose of topotecan administered in combination with a fixed dose of carmustine.
  • Determine the toxic effects of topotecan and carmustine in patients with recurrent primary malignant glioma.

OUTLINE: Topotecan is administered by an ambulatory infusion pump for 72 hours each week. Topotecan dose escalation is carried out in cohorts of three patients. Dose escalation is continued until toxic effects or disease progression is observed in these patients. Carmustine is administered over 1 hour every 6 weeks, on the same day as the first topotecan dose for that week.

Three patients will be treated at an initial dose level of topotecan, and if one of these patients experience dose limiting toxicity (DLT), an additional

3 patients must be treated at this dose level without further DLT in order for dose escalation to proceed. The MTD is the highest dose at which DLT occurs in no more than 1 of 6 patients.

Patients are evaluated after every 6 week cycle.

PROJECTED ACCRUAL: An estimated 18-36 patients will be entered.

Interventional
Phase 1
Primary Purpose: Treatment
Brain and Central Nervous System Tumors
  • Drug: carmustine
  • Drug: topotecan hydrochloride
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
May 2004
May 2004   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically proven recurrent primary malignant glioma

    • Measurable recurrent or residual primary central nervous system neoplasm confirmed by MRI

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance Status:

  • Karnofsky at least 60%

Hematopoietic:

  • Hematocrit greater than 29%
  • ANC greater than 1,500/mm^3
  • Platelet count greater than 125,000/mm^3

Hepatic:

  • SGOT less than 1.5 times upper limit of normal (ULN)
  • Bilirubin less than 1.5 times ULN

Renal:

  • Creatinine less than 1.5 mg/dL
  • BUN less than 25 mg/dL

Other:

  • Not pregnant
  • Effective contraceptive method must be used for the duration of the study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior chemotherapy within 6 weeks of study
  • No prior topotecan or carmustine treatment failure
  • No more than 1 prior chemotherapy regimen

Endocrine therapy:

  • Patients taking corticosteroids must be on stable dose for at least 2 weeks prior to study and the dose should not escalate over entry level

Radiotherapy:

  • No prior radiotherapy within 6 weeks of study

Surgery:

  • No prior surgical resection within 3 weeks of study

Other:

  • No concurrent medication that may interfere with study results
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002986
0224, DUMC-000224-01-1R4, DUMC-000224-00-2R3, DUMC-0348-99-2R2, DUMC-223-97-2, DUMC-229-98-2R1, SB-DUMC-229-98-2R1, NCI-G97-1242, CDR0000065521
Not Provided
Duke University
Duke University
Not Provided
Study Chair: Henry S. Friedman, MD Duke Cancer Institute
Duke University
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP